Karyopharm seeks FDA accelerated approval for Xpovio-ruxolitinib combo in myelofibrosis

PUBT · 1d ago
Karyopharm seeks FDA accelerated approval for Xpovio-ruxolitinib combo in myelofibrosis
  • Karyopharm filed an FDA sNDA seeking accelerated approval for XPOVIO (selinexor) with ruxolitinib in myelofibrosis.
  • Priority Review requested, implying a potential six-month review if granted.
  • Filing decision, including review timelines, expected in Q4 2026 following the FDA’s 60-day acceptance review.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608310730PR_NEWS_USPR_____NE36687) on August 31, 2026, and is solely responsible for the information contained therein.